Abstract
BACKGROUND AND OBJECTIVES: – Cholinergic degeneration in the nucleus basalis of Meynert (NBM) is implicated in the cognitive impairment seen in Parkinson disease (PD) and is being examined as a potential therapeutic target. We have previously shown the safety of delivering investigational autologous cell-based therapy, ie, peripheral nerve tissue (PNT), to the substantia nigra (SN) at the time of deep brain stimulation (DBS) surgery in PD (DBS-Plus). In this study, we assessed the safety and feasibility of simultaneously delivering that PNT to both the NBM and SN at the time of DBS.METHODS: – Two patients with idiopathic PD and mild cognitive impairment, who underwent clinically indicated bilateral globus pallidus internus DBS, were consented for participation. At the time of lead placement, reparative autologous PNT (sural nerve) was harvested and stereotactically delivered to the NBM and SN contralateral to the patients' more severe motor symptoms.RESULTS: – Delivery of PNT to both the SN and NBM was successfully achieved in both participants. There were no serious adverse events related to the delivery of the graft, and no adverse radiologic effects were observed. Both participants showed stable performance on standard PD testing. Neurocognitive testing at 18 months postoperatively in one participant showed expected decrements in certain domains and unique improvements in others.CONCLUSION: – We report the feasibility and preliminary safety data of stereotactic delivery of reparative autologous PNT to two separate unilateral targets at the time of DBS lead placement. We plan to continue exploring the potential for this investigational cell-based therapy to restore function to damaged networks in PD.
| Original language | English |
|---|---|
| Journal | Neurosurgery Practice |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2025 |
Bibliographical note
Publisher Copyright:© 2025
Funding
This work was supported by gifts to the UK Neurorestoration Center; Ann Hanley Neuroscience Fund; Pro's Players FORE Parkinson's; the National Center for Advancing Translational Sciences, through NIH grant UL1TR001998; and NIA 1R01AG081356. Samuel R. Daly is a Neuralink Innovation Research Fellow. Julie Gurwell received payment from Boston Scientific Deep Brain Stimulation for teaching courses on DBS programming, including travel payments. Jaimie Hixson received support from the Ann Hanley Neuroscience Fund. John Slevin has grants and/or contracts with the following: Amylyx, Cerevance, Ionis Pharma, Intrance Medical Systems Inc, NeuroDerm, Neuron23 Inc, Parkinson Foundation, Sumitomo Pharma, UCB Biopharma, and NIH U01 NS119562. He also sits on the Kentucky Spinal Cord & Head Injury Research Board within the Cabinet for Health & Public Services. Frederick A. Schmitt has grants from the NIA (P30AG072946 and U19AG068054), and he sits on the advisory board for the Alzhemier Foundation of America. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.
| Funders | Funder number |
|---|---|
| National Center for Advancing Translational Sciences (NCATS) | |
| Ann Hanley Neuroscience Fund | |
| National Institutes of Health (NIH) | UL1TR001998 |
| National Institute on Aging | 1R01AG081356, U19AG068054, P30AG072946 |
Keywords
- Autologous peripheral nerve transplant
- Cell therapy
- Deep brain stimulation
- Mild cognitive impairment
- Nucleus basalis of Meynert
- Parkinson disease
- Substantia nigra
ASJC Scopus subject areas
- Surgery
- Clinical Neurology
Fingerprint
Dive into the research topics of 'Autologous Peripheral Nerve Tissue Grafts Implanted into the Nucleus Basalis of Meynert and Substantia Nigra at the Time of Bilateral Deep Brain Stimulation in Parkinson Disease: A Report of 2 Cases'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver